Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

Inclusion Criteria

• Subjects previously treated with at least 1 dose of emricasan or placebo from clinical studies IDN-6556-07 (post orthotopic liver transplant due to HCV), IDN-6556-12 (NASH fibrosis), IDN-6556-14 (NASH cirrhosis), or IDN-6556-17 (NASH cirrhosis).
• Subjects able to provide written informed consent and able to understand and willing to comply with the requirements of the study.

Exclusion Criteria

• Use of controlled substances (including inhaled or injected drugs) or non-prescribed use of prescription drugs within 1 year of screening to the point of interfering with the subject's ability to comply, in the investigator's judgement, with study procedures.
• Treatment with an investigational drug following treatment with emricasan or placebo.
• Previous transplant unless subject was enrolled from IDN-6556-07 (post orthotopic liver transplant due to HCV).